Cargando…
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
OBJECTIVE: To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. DESIGN: Test negative case-control study. SETTING: Comm...
Autores principales: | Lopez Bernal, Jamie, Andrews, Nick, Gower, Charlotte, Robertson, Chris, Stowe, Julia, Tessier, Elise, Simmons, Ruth, Cottrell, Simon, Roberts, Richard, O’Doherty, Mark, Brown, Kevin, Cameron, Claire, Stockton, Diane, McMenamin, Jim, Ramsay, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116636/ https://www.ncbi.nlm.nih.gov/pubmed/33985964 http://dx.doi.org/10.1136/bmj.n1088 |
Ejemplares similares
-
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
Publicado: (2021) -
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
por: Whitaker, Heather J., et al.
Publicado: (2022) -
Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
por: Phumisantiphong, Uraporn, et al.
Publicado: (2023) -
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
por: Eyre, David W., et al.
Publicado: (2021)